LNTH NASDAQ
Lantheus Holdings, Inc.
1W: +0.2%
1M: -0.8%
3M: -2.8%
YTD: +48.6%
1Y: +93.6%
3Y: +51.7%
5Y: +270.6%
$99.96
+0.31 (+0.31%)
Weekly Expected Move ±0.5%
$99
$99
$100
$101
$101
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
17 relationships16
As Filer
counterparties named
1
As Counterparty
mentioned by others
3
Rel. Types
2022-11-14
Earliest Filing
2025-07-22
Latest Filing
target: 7
partner: 7
acquirer: 2
Counterparties (Filed by LNTH)
16 relationshipsCompanies named in LNTH's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Life Medical Group Limited | — | target | Sold Life Molecular Imaging Limited to Lantheus Medical Imaging, Inc. | 2025-07-22 | View |
| Life Healthcare Group Holdings Limited | — | target | Parent company of Life Medical Group Limited that sold Life Molecular Imaging Limited. | 2025-07-22 | View |
| Life Molecular Imaging Limited | — | target | Asset acquired by Lantheus Medical Imaging, Inc. in the transaction. | 2025-07-22 | View |
| Evergreen Theragnostics, Inc. | — | target | Target company acquired via statutory merger by Lantheus Medical Imaging, Inc. | 2025-04-01 | View |
| Evergreen Theragnostics, Inc. | — | target | Target company in a statutory merger to be acquired by Lantheus Medical Imaging, Inc. | 2025-01-28 | View |
| Shareholder Representative Services LLC | — | partner | Representative, agent, and attorney-in-fact for the Evergreen securityholders. | 2025-01-28 | View |
| Lantheus Medical Imaging, Inc. | LNTH | acquirer | Purchaser of Life Molecular Imaging Limited assets | 2025-01-13 | View |
| Lantheus Radiopharmaceuticals UK Limited | LNTH | acquirer | Purchaser of Life Molecular Imaging Limited assets | 2025-01-13 | View |
| Life Medical Group Limited | — | target | Seller of Life Molecular Imaging Limited assets | 2025-01-13 | View |
| Life Healthcare Group Holdings Limited | — | partner | Parent company of Seller and licensee of IP in South Africa | 2025-01-13 | View |
| Life Molecular Imaging Limited | — | target | Target company whose share capital is being acquired | 2025-01-13 | View |
| 201 Burlington Road Owner, LLC | — | partner | Landlord for the office and laboratory space lease amendment. | 2023-05-04 | View |
| POINT Biopharma Global Inc. | — | partner | Strategic collaboration to co-develop and commercialize PNT-2002 and PNT-2003 radiopharmaceutical therapies. | 2022-12-20 | View |
| Point Biopharma, Inc. | — | partner | Counterparty to license and collaboration agreements for PNT-2002 and PNT-2003 (referenced in Exhibit descriptions). | 2022-12-20 | View |
| POINT Biopharma Global Inc. | — | partner | Entered into license and collaboration agreements with Lantheus subsidiaries to co-develop and commercialize PNT-2002 an | 2022-11-14 | View |
| Point Biopharma, Inc. | — | partner | Counterparty to the license and collaboration agreements as referenced in the exhibit descriptions. | 2022-11-14 | View |
Mentioned As Counterparty
1 mentionsOther companies that named LNTH in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-02 | Other Events | View | |
| 2026-09-21 | Other Events | View | |
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-08-04 | Material Agreement; Officer/Director Change; Exhibits | Agreement | View |
| 2026-08-03 | Regulation FD; Other Events; Exhibits | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-05-01 | Officer/Director Change; Bylaws Amendment; Shareholder Vote; Exhibits | View | |
| 2026-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-12 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-08-11 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-08-06 | Results of Operations and Financial Condition; Regulation FD Disclosure; Other Events; Financial Sta | View | |
| 2025-07-22 | Completion of Acquisition or Disposition of Assets; Regulation FD Disclosure; Financial Statements a | Acquisition | View |
| 2025-05-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-05 | Amendments to Articles of Incorporation or Bylaws; Submission of Matters to a Vote of Security Holde | View | |
| 2025-04-01 | Completion of Acquisition or Disposition of Assets; Regulation FD Disclosure; Financial Statements a | Acquisition | View |
| 2025-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-30 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-01-28 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Regulation | Agreement | View |
| 2025-01-13 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR